Shandong Xinhua Pharmaceutical Company Limited (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xincat Pharmaceutical Company Limited, recently received a Drug Registration Certificate from the National Medical Products Administration for Saxagliptin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ) and (Ⅲ). According to the announcement dated 4 March 2026, the product is approved for improving blood sugar control in adult patients with type 2 diabetes, under diet and exercise therapy.

The tablets are included in the “National Drug Catalogue for Basic Medical Insurance, Work Related-Injury Insurance, and Maternity Insurance (2025)” as a Category B product. Official data indicate that Saxagliptin and Metformin Hydrochloride Sustained-release Tablets registered total sales of 419.00 million yuan in 2024 across China’s public medical institutions. The company expects this approval to broaden its hypoglycemic preparation portfolio and strengthen its overall market competitiveness while acknowledging that sales remain subject to policy changes and market fluctuations.